Sonodynamic therapy (SDT) is a minimally invasive targeted cancer therapy that uses focused low-intensity ultrasound (<10 MPa, <10 W/cm2) to activate sonosensitizer drugs. Once activated, these chemical compounds generate reactive oxygen species (ROS) to damage and kill cancer cells. A Phase I clinical trial has shown promising results for treating glioblastoma with SDT. We hypothesize that the efficacy of SDT can be improved by introducing lipid-coated microbubbles that produce a sonochemical effect that enhances ROS production. We investigate the hydrodynamics of a U.S. Food and Drug Administration (FDA)-approved microbubble, Lumason®, and a phospholipid-coated oxygen microbubble to predict the ultrasound parameters that induce sonoluminescence onset in biophysically relevant medium (e.g., water and blood) under clinical SDT conditions. The threshold pressures and frequencies for sonoluminescence with these therapeutic agents lie between 20 kHz – 1 MHz and 0.05 MPa – 1 MPa, respectively. The lipid-coated oxygen microbubble exhibits stronger sonoluminescence than the Lumason® microbubble, suggesting its use for improving SDT efficacy.

中文翻译：

---

破译用于声动力学治疗的脂质包被微气泡声波发光的流体动力学


声动力疗法 （SDT） 是一种微创靶向癌症疗法，它使用聚焦低强度超声 （<10 MPa， <10 W/cm2） 来激活声敏剂药物。一旦被激活，这些化合物会产生活性氧 （ROS） 来破坏和杀死癌细胞。I 期临床试验显示用 SDT 治疗胶质母细胞瘤的有希望的结果。我们假设可以通过引入脂质包被的微气泡来提高 SDT 的疗效，这些微气泡产生增强 ROS 产生的声化学效应。我们研究了美国食品和药物管理局 （FDA） 批准的微泡 Lumason® 和磷脂涂层氧微泡的流体动力学，以预测在临床 SDT 条件下在生物物理相关介质（例如水和血液）中诱导声发光的超声参数。使用这些治疗剂进行声夜发光的阈值压力和频率分别在 20 kHz – 1 MHz 和 0.05 MPa – 1 MPa 之间。脂质包被的氧微泡比 Lumason® 微泡表现出更强的声发光，表明其用于提高 SDT 疗效。